Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
Risa MotaiMichi SawabeShigenori KadowakiEiichi SasakiDaisuke NishikawaHidenori SuzukiShintaro BeppuHoshino TeradaNobuhiro HanaiPublished in: International journal of clinical oncology (2021)
wPTX-Cmab may be a suitable treatment option for R/M HNSCC patients with contraindications for platinum.